A Japanese research team recently published an editorial detailing two potential drug treatment breakthroughs for malignant pleural mesothelioma. Researchers from Hyogo College of Medicine have begun testing two new drugs that take separate approaches to eliminating cancerous cells, both with promising results. This is good news for pleural mesothelioma patients, who are often faced with limited treatment options and a short life expectancy after their diagnosis.
The first treatment involves a monoclonal antibody known as YS110. YS110 targets the protein CD26, which is overexpressed by mesothelioma cells, without harming healthy mesothelial cells. Approximately 85 percent of malignant pleural mesothelioma patients show an overexpression of CD26, which appears to be associated with apoptosis, or cell death, as well as tumor expansion. Tests on mesothelioma cells showed immediate results, with YS110 slowing the progression of the disease by 20 percent over a period of two days. After a successful Phase I trial involving 22 mesothelioma patients, the drug is being moved into the Phase II trial stage.
Blood Pressure Medication Shows Antitumor Properties
The second promising treatment method comes from a surprising source. Naftopidil is an alpha blocker or alpha-adrenergic antagonist used to regulate blood pressure. Recently, naftopidil and its chemically similar analogue, HUHS1015, have been successful in reducing malignant mesothelioma cell viability and halting the progression of tumors. Researchers are hopeful that naftopidil will prove to be an effective treatment for multiple types of asbestos-related diseases, including mesothelioma.
Mesothelioma, a rare and deadly form of cancer caused by asbestos exposure, currently has no cure and is notoriously resistant to many standard cancer treatments. The introduction of novel therapies such as YS110 and naftopidil could be a source of hope for malignant pleural mesothelioma patients. More testing is needed to determine whether these therapies will be an effective solution that can be widely distributed.
Philadelphia Mesothelioma Lawyers at Shein Law Obtain Compensation for Asbestos Exposure Victims in Pennsylvania
If you or a loved one is suffering from mesothelioma, lung cancer or another asbestos-related disease, call the Philadelphia mesothelioma lawyers at Shein Law. Our knowledgeable, experienced lawyers will thoroughly review the facts of your case and prepare an aggressive legal strategy to hold those responsible for your asbestos exposure accountable. With offices conveniently located in Philadelphia and Pennsauken, we help mesothelioma patients throughout Pennsylvania and New Jersey. Call us today at 1-877-SHEINLAW (743-4652) or contact us online to discuss your case with an experienced member of our legal team.